HomeCompareTNTRQ vs PFE

TNTRQ vs PFE: Dividend Comparison 2026

TNTRQ yields 4000000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TNTRQ wins by $4.994481689239762e+42M in total portfolio value
10 years
TNTRQ
TNTRQ
● Live price
4000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.994481689239762e+42M
Annual income
$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00
Full TNTRQ calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — TNTRQ vs PFE

📍 TNTRQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTNTRQPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TNTRQ + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TNTRQ pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TNTRQ
Annual income on $10K today (after 15% tax)
$340,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,245,100,666,965,326,000,000,000,000,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, TNTRQ beats the other by $4,245,100,666,965,326,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TNTRQ + PFE for your $10,000?

TNTRQ: 50%PFE: 50%
100% PFE50/50100% TNTRQ
Portfolio after 10yr
$2.497240844619881e+42M
Annual income
$2,497,118,039,391,368,600,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

TNTRQ
Analyst Ratings
3
Hold
2
Sell
Consensus: Hold
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TNTRQ buys
0
PFE buys
0
No recent congressional trades found for TNTRQ or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTNTRQPFE
Forward yield4000000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4.994481689239762e+42M$49.6K
Annual income after 10y$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00$26,258.71
Total dividends collected$4.994465620575748e+42M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: TNTRQ vs PFE ($10,000, DRIP)

YearTNTRQ PortfolioTNTRQ Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$400,010,700$400,000,000.00$9,153$693.39+$400.00MTNTRQ
2$14,954,099,039,486$14,953,671,028,037.38$8,593$849.25+$14954099.03MTNTRQ
3$522,475,570,786,797,700$522,459,569,900,825,500.00$8,336$1,066.78+$522475570786.79MTNTRQ
4$17,060,387,015,284,700,000,000$17,059,827,966,423,956,000,000.00$8,437$1,384.80+$17060387015284700.00MTNTRQ
5$520,629,757,399,644,800,000,000,000$520,611,502,785,538,400,000,000,000.00$9,013$1,875.40+$520629757399644831744.00MTNTRQ
6$14,848,629,939,995,690,000,000,000,000,000$14,848,072,866,155,271,000,000,000,000,000.00$10,306$2,680.72+$1.4848629939995692e+25MTNTRQ
7$395,786,651,827,842,740,000,000,000,000,000,000$395,770,763,793,806,900,000,000,000,000,000,000.00$12,820$4,101.38+$3.9578665182784276e+29MTNTRQ
8$9,859,464,902,403,675,000,000,000,000,000,000,000,000$9,859,041,410,686,219,000,000,000,000,000,000,000,000.00$17,673$6,826.70+$9.859464902403675e+33MTNTRQ
9$229,542,483,200,980,940,000,000,000,000,000,000,000,000,000$229,531,933,573,535,350,000,000,000,000,000,000,000,000,000.00$27,543$12,591.86+$2.2954248320098093e+38MTNTRQ
10$4,994,481,689,239,762,000,000,000,000,000,000,000,000,000,000,000$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00$49,560$26,258.71+$4.994481689239762e+42MTNTRQ

TNTRQ vs PFE: Complete Analysis 2026

TNTRQStock

Tintri, Inc. develops and markets an enterprise cloud platform combining cloud management software technology and a range of all-flash storage systems for virtualized and cloud environments in the United States and internationally. The company's platform provides large organizations and cloud service providers with public cloud capabilities inside their data centers and public cloud services. Its products and technologies include Tintri CONNECT, a proprietary software architecture for virtualized and cloud applications; Tintri OS, which helps the interaction between the virtualized infrastructure and the underlying storage serving that infrastructure; Tintri Global Center, an intelligent data and system management product; and VM Scale-out software, which creates resource pools of Tintri storage systems and optimizes the location of applications. The company's products and technologies also include predictive analytics solutions for customers to model their current and future storage requirements; ReplicateVM, the replication solutions for data protection and disaster recovery; SyncVM, a solution for copy data management; SecureVM, a solution for encryption of data-at-rest; Tintri Cloud Connector, which allows customers to use public cloud storage for storing snapshots; and storage systems, such as EC6000 all-flash systems, T800 hybrid-flash systems, and T1000 all-flash system. It also offers its products related support, installation, and training services. The company serves customer in education, financial services, insurance, healthcare, manufacturing, and automotive technology, as well as cloud service providers. Tintri, Inc. was founded in 2008 and is headquartered in Mountain View, California. On July 10, 2018, Tintri, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 8, 2019.

Full TNTRQ Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this TNTRQ vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TNTRQ vs SCHDTNTRQ vs JEPITNTRQ vs OTNTRQ vs KOTNTRQ vs MAINTNTRQ vs JNJTNTRQ vs MRKTNTRQ vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.